Strategic Moves Bolster Financial …

This article first appeared on GuruFocus.

Total Revenue: $1.1 million for Q3 2025, compared to $0.1 million in Q3 2024.
Total Operating Costs and Expenses: $6.5 million for Q3 2025, a decrease of 86% from $47.8 million in Q3 2024.
R&D Expenses: $1.2 million for Q3 2025, down 94% from $20 million in Q3 2024.
SG&A Expenses: $5.3 million for Q3 2025, a decrease of 43% from $9.4 million in Q3 2024.
Net Loss from Continuing Operations: $13.1 million or $3.25 per share for Q3 2025, compared to $48.3 million or $12.01 per share in Q3 2024.
Cash and Cash Equivalents: $121.1 million as of September 30, 2025.
Cash Runway: Extended into 2028 following the sale of FibroGen China.
FibroGen China Sale: Completed for approximately $220 million, including $135 million net cash held in China.

Release Date: November 10, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

FibroGen Inc (NASDAQ:FGEN) completed the sale of FibroGen China to AstraZeneca for approximately $220 million, significantly enhancing their cash position and extending their cash runway into 2028.
The company is progressing with FG-3246, a potential first-in-class antibody drug conjugate targeting CD46, with promising early efficacy signals in metastatic castration-resistant prostate cancer (mCRPC).
FibroGen Inc (NASDAQ:FGEN) has a clear regulatory path forward for Roxadustat as a treatment for anemia due to lower-risk myelodysplastic syndromes, following a successful Type C meeting with the FDA.
The company has significantly reduced its operating costs, with a 70% reduction in total operating costs and expenses projected for full-year 2025 compared to 2024.
FibroGen Inc (NASDAQ:FGEN) has a strengthened financial position, with $121.1 million in cash and equivalents as of September 30, 2025, and plans to invest in US pipeline opportunities.

FibroGen Inc (NASDAQ:FGEN) reported a net loss from continuing operations of $13.1 million for the third quarter of 2025, although this is an improvement from the previous year.
The company faces potential thrombotic risks in the Roxadustat-MDS pivotal trial, which could impact patient enrollment and trial costs.
The cost of the Phase 3 trial for Roxadustat is estimated to be $50 million to $60 million, which could affect the company’s cash runway if conducted independently.
FibroGen Inc (NASDAQ:FGEN) has a liability related to royalties associated with their royalty financing with NovaQuest Capital Management, impacting future revenue streams.
The company may need to raise additional capital to support the cost of running the Phase 3 study for Roxadustat, potentially affecting their financial strategy.

Q: Can you provide insights on the potential thrombotic risk in the Roxadustat-MDS pivotal trial and its impact on patient screening and trial costs? A: Thane Wettig, Interim CEO, explained that the thrombotic risk’s impact on patient screening will depend on the exclusion criteria aligned with the FDA and the trial data. It’s too early to estimate the proportion of patients affected. The trial is estimated to cost $50-60 million, and CFO David Delucia noted that the current cash guidance into 2028 does not include this trial, which could affect cash runway if conducted independently.

Q: How does FibroGen view the prostate cancer landscape, particularly regarding CD46’s positioning among other targets like PSMA and Bombesin? A: Thane Wettig highlighted that CD46 has a high degree of concordance with PSMA expression. The company is exploring expression levels through the Phase 2 monotherapy trial, which will provide more data on CD46’s correlation with other targets. Academic work is ongoing, but it’s premature to comment on CD46’s overlap with other targets.

Q: What are the expectations for the top-line data from the FG-3246 IST study in prostate cancer? A: Thane Wettig stated that a consistent result with the preliminary efficacy estimate of 10.2 months from the Phase 1b portion would be encouraging. The data will be analyzed based on prior ARPI treatments, as higher numbers of ARPIs correlate with declining rPFS.

Q: Can you clarify the $63 million liability on the balance sheet? A: David Delucia clarified that the liability is related to royalties from a financing agreement with NovaQuest Capital Management, not milestone payments for ADC assets. FibroGen owes 22.5% of royalties from Roxadustat sales in certain territories to NovaQuest.

Q: What are the future milestone payments related to the ADC assets? A: Thane Wettig explained that if FibroGen decides to move FG-3246 into Phase 3, they would exercise an option to acquire Fortis Therapeutics for $80 million. An additional $75 million would be due upon approval in the US or Europe, with no further royalties to Fortis.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Source link

Leave a Reply Cancel reply